251456-60-7 Usage
Description
M344, also known as a cell-permeable amide analog of Trichostatin A, is a potent inhibitor of histone deacetylases (HDACs). It is characterized by its ability to inhibit maize HDAC (IC50 = 100 nM) and human HDAC1 (IC50 = 46 nM), with a three-fold selectivity for HDAC6 over HDAC1. M344 is known to induce differentiation, inhibit proliferation, and enhance the sensitivity of human cancer cells to radiation, promoting cell cycle arrest and apoptosis.
Uses
Used in Pharmaceutical Industry:
M344 is used as a histone deacetylase inhibitor for its ability to inhibit HDACs, which has potential applications in the treatment of various cancers. It modulates cellular processes by altering the acetylation state of histones, affecting gene expression and contributing to the development of cancer.
Used in Cancer Research:
M344 is used as a research tool for studying the role of HDACs in cancer cell biology. It helps researchers understand the mechanisms of action and potential therapeutic targets for cancer treatment.
Used in Anticancer Applications:
M344 is used as an anticancer agent, particularly in enhancing the sensitivity of human squamous carcinoma cells to radiation. It promotes cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells (ED50 = 2.3 μM), making it a promising candidate for cancer therapy.
Used in Drug Development:
M344 is used in the development of novel drug delivery systems to improve its delivery, bioavailability, and therapeutic outcomes in cancer treatment. Various organic and metallic nanoparticles have been employed as carriers for M344 delivery, aiming to enhance its efficacy against cancer cells.
Biological Activity
Histone deacetylase inhibitor (IC 50 = 100 nM). Induces terminal cell differentiation and causes an increase in hyperacetylated histone H4. Antiproliferative agent; suppresses the growth of human endometrial and ovarian cancer cells by inducing cell cycle arrest and apoptosis.
Biochem/physiol Actions
Cell permeable: yes
references
[1]. jung m, brosch g , kolle d, et al. amide analogues of trichostatin a as inhibitors of histone deacetylase and inducers of terminal cell differentiation. journal of medicinal chemistry, 1999, 42 (22): 4669-4679.[2]. yeung a, bhargava rk, ahn, r, et al. hdac inhibitor m344 suppresses mcf-7 breast cancer cell proliferation. biomedicine & pharmacotherapy, 2012, 66 (3): 232-236.[3]. furchert se, lanvers-kaminsky c , jurgens h , et al. inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. international journal of cancer, 2007, 120 (8): 1787-1794.[4]. ying h, zhang yh , zhou x , et al. selective histonedeacetylase inhibitor m344 intervenes in hiv-1 latency through increasing histone acetylation and activation of nf-kappab. plos one, 2012, 7 (11): e48832.
Check Digit Verification of cas no
The CAS Registry Mumber 251456-60-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,1,4,5 and 6 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 251456-60:
(8*2)+(7*5)+(6*1)+(5*4)+(4*5)+(3*6)+(2*6)+(1*0)=127
127 % 10 = 7
So 251456-60-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H25N3O3/c1-19(2)14-10-8-13(9-11-14)16(21)17-12-6-4-3-5-7-15(20)18-22/h8-11,22H,3-7,12H2,1-2H3,(H,17,21)(H,18,20)
251456-60-7Relevant articles and documents
FILAGGRIN PRODUCTION PROMOTER, THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH REDUCTION IN PRODUCTION OF FILAGGRIN, AND METHOD FOR SCREENING FOR SAID THERAPEUTIC AGENT
-
Page/Page column, (2015/06/16)
The present invention provides a highly effective substance having a filaggrin production-promoting action. The present invention also provides a therapeutic agent useful for treating a skin disease, in particular, atopic dermatitis associated with reduce
Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation
Jung, Manfred,Brosch, Gerald,K?lle, Doris,Scherf, Hans,Gerh?user, Clarissa,Loidl, Peter
, p. 4669 - 4679 (2007/10/03)
Inhibitors of histone deacetylase (HD) bear great potential as new drugs due to their ability to modulate transcription and to induce apoptosis or differentiation in cancer cells. We have described previously analogues of the complex natural HD inhibitors trapoxin B and trichostatin A with activities in the submicromolar range. Here we report structure-activity relationship analyses of further analogues of trichostatin A with respect to in vitro inhibition of maize HD-2 and their ability to induce terminal cell differentiation in Friend leukemic cells. This is the first report that shows the correlation between HD inhibitory activity and action on cancer cells on a larger series of similar compounds. Only the compounds that inhibit HD induce differentiation and/or exert antiproliferative activities in cell culture. Our studies support the use of in vitro systems as screening tools and provide structure-activity relationships that merit further investigation of this interesting target.
